17th June 2026

Wegovy HD 7.2 mg FlexTouch Pen: Know About the New Dose of Wegovy Weight Loss Injection UK

By Mr Suhail Jamil

Trustpilot

Key Takeaways

The MHRA has approved a new dedicated Wegovy 7.2mg pen, allowing the maximum maintenance dose in a single weekly injection.
Clinical trials show patients on 7.2mg lost an average of 20.7% of their body weight (for those completing the full trial duration).
This "plateau breaker" dose is only for patients who have already stabilised on the 2.4mg dose but need further support.

Wegovy 7.2mg UK Update

Say goodbye to the hassle of multiple weekly injections.

The MHRA has approved a new Wegovy 7.2mg pen (the maximum maintenance dose of the Wegovy weight loss injection) that allows eligible adults with obesity to receive the maximum weekly semaglutide dose in a single injection instead of three separate injections.

Regulatory Timeline:

January 2026: The MHRA approved increasing Wegovy's maximum weekly dose to 7.2mg. At that time, patients had to take three 2.4mg injections on the same day to reach the dose.
April 2026: The MHRA approved a new dedicated 7.2mg pen in the UK. The new pen delivers the full 7.2mg dose in a single weekly injection.

About Wegovy HD 7.2 mg vs ‘Standard’ Dose

Understand the science behind Wegovy 7.2mg, how the new maximum dose compares with the standard 2.4mg treatment, what the latest clinical evidence shows, and which adults may benefit most from this higher-strength option.

Maintenance Dosing Comparison

A clinical overview of Standard 2.4mg vs. High-Dose 7.2mg pathways.

Feature	Standard Maintenance (2.4 mg)	High-Dose Maintenance (7.2 mg)
Primary Indication	Baseline maintenance dose for chronic weight management.	"Plateau breaker" for patients needing further support after stabilising on 2.4 mg.
Average Weight Loss (72 weeks)	~17.5% reduction in body weight.	~20.7% reduction in body weight.
Patients losing >25% body weight	16.7% of patients.	33.2% of patients (double the rate of the standard dose).
Gastrointestinal Side Effects	Common (~61% reported mild to moderate GI symptoms).	More frequent (~71% reported GI symptoms).
Dysaesthesia (Altered Skin Sensation)	Rare (~4.9% of trial participants).	More common (~19% to 23% reporting tingling, burning, or sensitivity).
Administration	One single-dose pre-filled pen injected weekly.	Three separate 2.4 mg injections taken sequentially (until single-dose 7.2 mg pens are widely distributed).
UK Approval Status	Fully Available	MHRA Approved(Single pen approved April 2026)

Disclaimer: Data is sourced from peer-reviewed clinical trials and official MHRA updates. This guide is provided for educational purposes and does not constitute medical advice. Individual treatment plans should always be discussed during your consultation.

Wegovy HD 7.2mg in the UK: A Higher Dose for Better Weight Loss

Last updated: 17 June, 2026

The MHRA-approved Wegovy 7.2 mg Flex Touch pen is a multi-dose device designed to deliver the maximum semaglutide maintenance dose in a single weekly subcutaneous injection.

Available clinical data suggest Wegovy HD (semaglutide) 7.2 mg may lead to greater weight loss than the standard Wegovy dose in adults who have not responded sufficiently to lower doses.

When is Wegovy 7.2 mg prescribed? +

Wegovy HD (semaglutide) 7.2 mg is a higher-strength dose used for adults with obesity who require additional weight loss support when the standard 2.4 mg maintenance dose is no longer sufficient.

How to use Wegovy 7.2mg Pen?+

The 7.2 mg Wegovy dose is now delivered as a single weekly injection, eliminating the need to take three separate 2.4 mg injections. Each pen is single-use and delivers the full weekly dose at once. A standard one-month course is supplied as four pre-filled pens.

Do I need a prescription and medical supervision to use the 7.2 mg Wegovy pen? +

Yes. It is strictly prescribed under medical supervision as part of a carefully managed step-up dosing plan. Eligibility is based on your individual response and tolerability. You should never adjust your dosage without consulting a qualified healthcare professional.

Patient Eligibility: Is Wegovy 7.2 mg right for you?

You are only eligible for the 7.2mg dose if you meet the following clinical criteria:

✓

Established on 2.4mg: You have completed the standard titration and been stable on 2.4mg for at least four weeks.

✓

BMI Criteria: You have a BMI of 30 or above (or 27+ with weight-related comorbidities).

✓

Clinical Need: Your weight loss has plateaued on the 2.4mg dose, and a clinician has confirmed you require further pharmacological support.

Can I start straight on the 7.2mg dose?

No. The 7.2mg pen is only for people whose bodies are already used to the medicine. You must follow the standard step-up plan first.

How Effective is Wegovy 7.2mg?

Wegovy 7.2mg works in the same way as lower doses but offers significantly greater strength to help overcome weight-loss plateaus.

Clinical Efficacy Spotlight

Break Through Your Plateau

Average body weight reduction at 72 weeks

-2.4%

-17.5%

-20.7%

Placebo

Wegovy®
2.4 mg

Wegovy® HD
7.2 mg

1in3

With Wegovy HD, approximately 1 in 3 patients achieved ≥25% weight loss.

*Efficacy estimand data sourced from Novo Nordisk 72-week STEP trials. Outcomes depend on adherence to prescribed titration, clinical oversight, and lifestyle modifications.

Clinical Weight Loss Results: In 72-week clinical trials, patients taking the 7.2mg dose lost an average of 18.7% of their total body weight. For patients who adhered to the treatment for the full duration, the average rose to 20.7%.
Is it three times more effective? Even though the dose has three times the medicine, the weight loss doesn't triple. It gives a solid extra boost (from ~15% to ~20%) rather than a multiplied result.

What is the estimated cost of Wegovy 7.2mg privately in the UK?

The estimated private cost of the 7.2mg Wegovy dose in the UK typically ranges between £248.97 and £329.00 for a 4-week supply.

Estimated Prices by Top UK Providers

Here are the typical private costs across several major UK providers. Prices may vary depending on whether you are supplied with one dedicated 7.2mg pen or three 2.4mg pens.

Asda Online Doctor
£248.97(supplied as three 2.4mg pens)
Ashcroft Pharmacy
£249.00(supplied as single 7.2mg pens)
MedExpress / Cloud Pharmacy
£279.99
Superdrug Online Doctor
£285.00
The Independent Pharmacy
£285.97
Mayfair Weight Loss Clinic
£329.00

Worth knowing

Availability: The 7.2mg dose is supplied either as three 2.4mg pens taken together or, from 1 June 2026, a single 7.2mg pen, depending on the pharmacy's stock. Watch out for headline prices like £49–£75 — those are starter doses or first-order discounts, not the 7.2mg maintenance price.

Side Effects of Wegovy HD 7.2 mg

Because it contains three times the active ingredient of the standard maintenance dose, you may experience the usual side effects more frequently.

Side Effect	Wegovy 2.4 mg	Wegovy 7.2 mg
Nausea	~30%	~35%
Vomiting	~16%	~22%
Constipation	~19%	~20%
Abdominal Pain	~9%	~12%

Note: Diarrhoea, dizziness, gas, bloating, and heartburn are also frequently reported. Hair loss can also occur, though this is typically linked to rapid weight loss rather than the medication itself. [source]

About Dysaesthesia

What is Dysaesthesia? +

Dysaesthesia is a newly identified side effect more common with the 7.2mg dose, affecting roughly 20% of patients. It causes an altered, sensitive, burning, or tingling sensation on the skin. For the vast majority of patients, it is mild and resolves naturally over time without the need to stop treatment.

Will my stomach side effects be worse on the higher dose? +

Gastrointestinal side effects, such as nausea and stomach cramps, are slightly more frequent on the 7.2mg dose (70.8% compared to 61.2% on the 2.4mg dose). However, they are highly manageable; in clinical trials, only 3.3% of patients had to stop their treatment due to these side effects.

⚠︎Serious Risks and Warnings

While rare, you must contact a healthcare provider immediately if you experience:

•

Pancreatitis: Severe abdominal pain radiating to the back with vomiting.

•

Gallbladder Problems: Upper right stomach pain, fever, or jaundice.

•

Kidney Injury: Dehydration resulting from severe vomiting/diarrhoea.

•

Stomach Paralysis (Gastroparesis): Delayed stomach emptying.

Frequently Asked Questions

Is Wegovy 7.2 mg available on the NHS? +

No, the 7.2 mg dose of Wegovy is currently not available on the NHS. While the MHRA has licensed it for use in the UK, it is currently limited to private prescription. NHS access requires a positive recommendation from NICE regarding clinical and cost-effectiveness.

Does the Wegovy 7.2 mg dose use a different active ingredient? +

No, It contains the same active ingredient (semaglutide) at a higher concentration to further suppress appetite and slow gastric emptying.

Useful Resources

•

MHRA Approval Updates for Semaglutide (2026).

•

Novo Nordisk Clinical Efficacy and Safety Data for Chronic Weight Management.

•

Summary of Product Characteristics (SmPC) & Patient Information Leaflet (PIL).

•

Wegovy (semaglutide) Medication Guide. Novo Nordisk.

Disclaimer: This article is for informational purposes only and does not substitute professional medical advice. Always consult with your clinician or Ashcroft prescribing pharmacist before making changes to your weight management plan.

Find Wegovy at Ashcroft Pharmacy